AbbVie Inc. (BKK:ABBV19)

Thailand flag Thailand · Delayed Price · Currency is THB
7.55
-0.05 (-0.66%)
At close: Oct 7, 2025
-0.66%
Market Cap13.35T
Revenue (ttm)1.89T
Net Income (ttm)120.91B
Shares Outn/a
EPS (ttm)68.21
PE Ratio110.38
Forward PE17.80
Dividendn/a
Ex-Dividend Daten/a
Volume142,526
Average Volume53,910
Open7.50
Previous Close7.60
Day's Range7.40 - 7.65
52-Week Range6.85 - 8.00
Betan/a
RSI60.40
Earnings DateOct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Stock Exchange of Thailand
Ticker Symbol ABBV19
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.